U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT07509515) titled 'QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.' on March 29.
Brief Summary: The study will evaluate the safety and efficacy of QLC5513 alone or in combination with QL1706 in patients with advanced or metastatic triple-negative breast cancer (TNBC) who had received >=1 line of prior systematic therapy.
Study Start Date: April 15
Study Type: INTERVENTIONAL
Condition:
Triple-negative Breast Cancer (TNBC)
Intervention:
DRUG: QLC5513
Participants of Arm A will receive QLC5513 16 mg/kg intravenously on day 1 and day 8 every 3 weeks. QLC5513 is a Trop2-targeting ADC with a proprietary ...